(Reuters) - ZURICH, July 26 - Swiss-based pharmaceuticals firm
Roche Holding AG said on Thursday the European
Commission had approved its long-acting drug Mircera to treat
anaemia associated with chronic kidney disease.
The potential blockbuster drug belongs to a class of
medicines known as erythropoiesis stimulating agents. They are
used to boost red blood cells in anaemia patients to help avoid
the need for blood transfusions.
Read more at Reuters.com Government Filings News
Roche Holding AG said on Thursday the European
Commission had approved its long-acting drug Mircera to treat
anaemia associated with chronic kidney disease.
The potential blockbuster drug belongs to a class of
medicines known as erythropoiesis stimulating agents. They are
used to boost red blood cells in anaemia patients to help avoid
the need for blood transfusions.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment